Pfizer Touts Tukysa in Front-Line Breast Cancer After Phase III Victory - Pharmaceutical Technology

Pfizer touts Tukysa in front-line breast cancer after Phase III victory

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if it were to be approved in this setting.The post Pfizer touts Tukysa in front-line breast cancer after Phase III victory appeared first on Clinical Trials Arena.

Pfizer touts Tukysa in front-line breast cancer after Phase III victory - Pharmaceutical Technology

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if it were to be approved in this setting.

Pfizer claims first-line success for Tukysa in breast cancer Phase 3 trial

Pfizer’s Tukysa succeeded as a first-line maintenance therapy in combination with other standard-of-care drugs for certain metastatic breast cancer patients, the company said Tuesday. In a Phase 3 trial, the TKI inhibitor was given in ...